Exploring Mechanisms and Morphology of QT Interval Prolongation

Exploring Mechanisms and Morphology of QT Interval Prolongation - An Inheritable as Well as an Inducible Phenomenon

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03291145

Acronym

TriQarr

Enrollment

Registered

2017-09-25

Start date

2017-06-27

Completion date

2019-01-01

Last updated

2019-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long Qt Syndrome 1-2, Sudden Cardiac Death

Keywords

Long QT Syndrome

Brief summary

The projects will try and optimise the risk stratification for patients with Long QT syndrome by investigating how the exposure of physical and acoustic stress will affect the QT-dynamics and if beta blockers protect against arrhythmias by suppressing this dynamic QT-prolongation. Furthermore, the project will investigate the effects of Spironolactone on the QT-dynamics tested by Brisk Standing. First, patients are tested with known arrhythmic triggers and they are then administered thier normal dose of beta blockers. Hereafter, Brisk Standing test is performed and the patients are on Spironolactone for seven days. After seven days treatment the Brisk Standing is repeated.

Detailed description

The aim of the projects is to try and optimise the risk stratification for patients with Long QT syndrome by investigating how the exposure of physical and acoustic stress will affect the QT-dynamics and if beta blockers protect against arrhythmias by suppressing this dynamic QT-prolongation. Furthermore, the project will investigate the effects of Spironolactone on the QT-dynamics tested by Brisk Standing. First, patients are tested with known arrhythmic triggers and they are then administered thier normal dose of beta blockers. Hereafter, Brisk Standing test is performed and the patients are on Spironolactone for seven days. After seven days treatment the Brisk Standing is repeated.

Interventions

DRUGBeta Blockers

With and without Beta Blockers

DRUGSpironolactone

Brisk Standing before and after seven days treatment with Spironolactone

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Verified Long QT syndrome mutation, subtype 1 or 2. * over 18 years of age

Exclusion criteria

* Atrioventricular block, * Left bundle branch block, * Left ventricular hypertrophy, * Pace rhythm, * ST-deviations \>1 mm), * Left ventricular ejection fraction \<50 % and significant valvulopathy, * Unstable psychiatric disease * Unstable cardiovascular disease.

Design outcomes

Primary

Measure	Time frame	Description
QTc	7 days	Corrected QT

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026